Mounjaro and Gallstones: What NHS Guidance and Clinical Evidence Say

Does Mounjaro cause gallstones?

Not directly, but the relationship is real and worth understanding. When the body loses weight quickly, the liver sheds extra cholesterol into bile, and bile can become more concentrated, making it easier for stones to crystallise. This happens with any effective weight-loss intervention, including low-calorie diets and bariatric surgery. Because tirzepatide can produce substantial weight loss relatively quickly, the same mechanism applies, and if you are considering whether to buy tirzepatide peptide through any route, understanding this context is part of making an informed decision. The Mounjaro SmPC (the medicine's official prescribing information, published on the eMC) lists gallbladder disorders, including gallstones, as an adverse reaction seen during clinical trials.

The SURMOUNT trial programme, which ran across thousands of adults over 72 weeks, reported gallbladder-related events. They were not common, but they were more frequent in the tirzepatide group than in those receiving placebo, which is consistent with the weight-loss-speed hypothesis. That does not mean treatment should be avoided, but it does mean the risk should sit on the table during your consultation rather than come as a surprise later.

Worth knowing: gallstones can also be present before treatment starts and remain silent. Losing weight sometimes causes previously silent stones to become symptomatic. This is not always a sign that the medicine caused them; it may simply be that weight loss shifted the conditions in the gallbladder enough to provoke an episode.

Who is most likely to be affected, and how does a prescriber assess it?

Certain factors raise the baseline risk of gallstone problems: being female, being over 40, a personal history of gallstones or previous gallbladder surgery, a family history of the condition, insulin resistance, and significant prior weight fluctuations. None of these automatically rules out Mounjaro treatment, but they all inform the clinical conversation.

A prescriber looking at your case will consider whether you have active gallbladder disease, whether you have had your gallbladder removed already (which removes one risk and is relevant in a different way), and how fast weight loss is likely to be given your starting point and dose trajectory. Our clinical team reviews this as part of every consultation; you can read more about how that process works on our Mounjaro overview page.

If you have a history of gallstones and are wondering specifically whether a prescriber will take you on, our page covering prescribing Mounjaro with a gallstone history goes into that in more detail. The short answer is that it depends on your current gallbladder status and whether your condition is active or resolved.

What symptoms should prompt urgent help during treatment?

The NHS medicines guidance for tirzepatide flags gallbladder symptoms as something to watch for. Seek medical help promptly if you develop sudden, severe pain in the upper right side of your abdomen, pain that spreads to your right shoulder, fever, chills, or yellowing of the skin or whites of the eyes. These can indicate a gallstone has moved into a duct, which can become serious quickly.

Nausea and upper abdominal discomfort are also very common early in Mounjaro treatment as straightforward gastrointestinal side effects, so not every stomach complaint signals a gallbladder problem. The distinction that matters is severity and location: a dull ache across the middle of the abdomen after starting a new dose is different from sharp, colicky pain concentrated under the right ribcage. If you are unsure, contact your prescriber or call 111. Report any suspected side effects, including gallbladder symptoms, via the MHRA Yellow Card scheme, which helps regulators track real-world safety signals for all medicines including Mounjaro.

Keeping your pen in the fridge door is a small practical habit; checking in with how you feel each week after a new dose is a rather more important one. Changes that worry you are worth raising before they escalate.

How does the NHS approach this risk, and where does private treatment fit?

The NHS medicines information for tirzepatide lists gallbladder problems as a side effect that people on the medicine should be aware of, alongside the advice to seek medical help if symptoms arise. NHS prescribers, whether in specialist weight management services or through the newer GP prescribing route, are expected to document relevant gallbladder history before initiating treatment. The same standard applies in the private sector under GPhC guidance.

For people exploring private access, our NHS versus private Mounjaro page sets out the differences in criteria, timelines, and process, and those who want to understand the NHS route in full can also visit our dedicated page on how to buy Mounjaro through the NHS. On cost, the Mounjaro pricing page explains what is included in private treatment fees and why the price varies by dose and provider. The gallstone risk does not change depending on whether your prescription is NHS or private; what changes is who monitors you and how.

If you are already on treatment and your circumstances change, our aftercare team is available seven days a week. Gallbladder symptoms that develop mid-treatment are exactly the kind of thing to flag rather than wait out.